医学
甲状腺癌
甲状腺
甲状腺癌
癌症研究
甲状腺髓样癌
正电子发射断层摄影术
生长抑素受体
放射性核素治疗
癌症
内科学
肿瘤科
成纤维细胞活化蛋白
生长抑素
甲状腺结节
病理
甲状腺球蛋白
闪烁照相术
靶向治疗
多塔
癌
受体
分子成像
淋巴
核医学
化学免疫疗法
抗原
临床试验
内分泌学
阶段(地层学)
作者
Archana Sridhar,Noha Behairy,Joanna Kłubo-Gwieździńska
标识
DOI:10.1210/clinem/dgag310
摘要
The incidental thyroid uptake of radiolabeled ligands used in positron emission tomography/computed tomography (PET/CT) targeting cell-surface proteins is observed in up to 6% of all scans. While diffuse thyroid uptake of ligands targeting somatostatin receptor type 2 (SSTR2), prostate-specific membrane antigen (PSMA), fibroblast activation protein (FAPI), or choline is observed in normal thyroid or usually signifies a benign thyroid abnormality, a heterogeneous or focal uptake is associated with malignant lesions in up to 19.7% of patients. The PET/CTs utilizing these ligands are characterized by decreased diagnostic sensitivity for detection of thyroid cancer metastases compared with cross-sectional imaging or 18-fluorodeoxyglucose PET/CT but are highly specific for detection of a subset of thyroid cancers characterized by a high target protein expression. Increased uptake of radiolabeled ligands targeting SSTR2, PSMA, FAPI, integrin αvβ3, and minigastrin can be used for patient selection for peptide receptor radionuclide therapy (PRRT). PRRT can be applied in clinical trials and/or off-label for patients with advanced radioactive iodine-refractory thyroid cancer who have limited treatment options or for medullary thyroid carcinoma of neuroendocrine origin. The PRRT-induced disease control rate approaches 60% and PRRT is well tolerated with limited side effects. Efficacy could be improved with careful patient selection based on the expression of molecular targets and their function, quantified by standard uptake values in diagnostic PET/CT imaging. Adopting an individualized dosimetry-based approach and synthesizing ligands with better tumor retention and residence time may help optimize treatment response.
科研通智能强力驱动
Strongly Powered by AbleSci AI